Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-06-20
2006-06-20
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100
Reexamination Certificate
active
07063849
ABSTRACT:
Use of HIV-1 gp120 and gp160 proteins which have been modified in the V3 loop for preparing vaccine compositions and formulations containing them which induce a systemic and mucosal immunity.Use of a recombinant HIV-1 Env protein, in which the V3 loop is partially or completely deleted, for preparing a vaccine composition which is capable of inducing an immunity which is at the same time humoral, cellular and mucosal with respect to HIV-1.The vaccine composition comprises:a recombinant Env protein as defined above,optionally at least one compound selected from the group consisting of: (1) the vaccination adjuvants selected from the group consisting of derivatives comprising divalent or trivalent ions: aluminium hydroxide or calcium phosphate, and muramylpeptide derivatives and (2) liposomes andoptionally at least one pharmaceutically acceptable vehicle.
REFERENCES:
patent: 5910306 (1999-06-01), Alving et al.
patent: 6048531 (2000-04-01), Mannino et al.
Hoth, D. F., et al., 1994, “HIV vaccine development: a progress report”, Ann. Int . Med. 8(7):603-611.
Stott, J., and N. Almond, 1995, “Assessing animal models of AIDS”, Nat. Med. 1(4):295-297.
Graham, B. S., and P. F. Wright, 1995, “Candidate AIDS vaccines”, New Engl. J. Med. 333(20):1331-1339.
Haynes, B. F., et al., 1996, “Update on the issues of HIV vaccine development”, Ann. Med. 28:39-41.
Haynes, B. F., 1996, “HIV vaccines: where we are and where we are going”, Lancet 348:933-937.
Kent, S. J., et al., 1997, “Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection”, J. Immunol. 158:807-815.
Lee, T.-H., 1997, “Acquired immunodeficiency disease vaccines: design and development”, inAIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition, DeVita, Jr., V. T., et al., eds., Lippincott-Raven Publishers, Philadelphia, PA, pp. 605-616.
Letvin, N. L., 1998, “Progress in the development of an HIV-1 vaccine”, Science 280:1875-1880.
Burton, D. R., and J. P. Moore, 1998, “Why do we not have an HIV vaccine and how we can we make one?”, Nat. Med. 4(5):495-498.
Moore, J. P., and D. R. Burton, 1999, “HIV-1 neutralizing antibodies: how full is the bottle?”, Nat. Med. 5(2):142-144.
Nathanson, N., and B. J. Mathieson, 2000, “Biological considerations in the development of a human immunodeficiency virus vaccine”, J. Infect. Dis. 182:579-589.
Johnston, M. I., 2000, “The role of nonhuman primate models in AIDS vaccine development”, Mol. Med. 6:267-270.
Bende, S., and M. I. Johnston, 2000, “Update: search for an AIDS vaccine”, AIDS Reader, Sep., 526-538.
Feinberg, M. B., and J. P. Moore, 2002, “AIDS vaccine models: challenging challenge viruses”, Nat. Med. 8(3):207-210.
Lavallee, C., and L. Thibodeau, 1996, “Clonage, expression et caracterisation de gp160 du VIH-1, portant des deletions partielles ou totales dans la boucle V3”, C.R. Acad. Sci. Paris, Sciences de la vie/Life sciences, 319:983-990.
Burton, D. R., et al., 1998, “Why do we not have HIV vaccine and how can we make one?”, Nature Med. Vaccine Suppl. 4(5):495-498.
Moore, J. P., et al., 1999, “HIV-1 neutralizing antibodies: how full is the bottle?”, Nature Med. 5(2):142-144.
Lavallee Claude
Thibodeau Lise
Fondation Mondiale Recherche et Prevention Sida
Morgan Lewis & Bockius
Parkin Jeffrey S.
LandOfFree
Use of HIV-1 gp120 and gp160 proteins modified in the v3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of HIV-1 gp120 and gp160 proteins modified in the v3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of HIV-1 gp120 and gp160 proteins modified in the v3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3628939